NASDAQ:MBRXMoleculin Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Moleculin Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.08 +0.01 (+0.93 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$1.02Now: $1.08▼$1.1050-Day Range$0.97MA: $1.11▼$1.4752-Week Range$0.32Now: $1.08▼$1.97Volume1.59 million shsAverage Volume4.58 million shsMarket Capitalization$65.24 millionP/E RatioN/ADividend YieldN/ABeta2.4 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, Moleculin Biotech has a potential upside of 131.5% from its current price of $1.08.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMoleculin Biotech has received 208 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMoleculin Biotech has received 175 “underperform” votes. (Add your “underperform” vote.)Community SentimentMoleculin Biotech has received 54.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote “Outperform” if you believe MBRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.30% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 7.87% of the stock of Moleculin Biotech is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to decrease in the coming year, from ($0.33) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBRX Previous Symbol CUSIPN/A CIK1659617 Webwww.moleculin.com Phone713-300-5160Debt Debt-to-Equity Ratio0.02 Current Ratio4.26 Quick Ratio4.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book3.18Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-13,200,000.00 Net MarginsN/A Return on Equity-92.44% Return on Assets-58.87%Miscellaneous Employees9 Outstanding Shares60,403,000Market Cap$65.24 million Next Earnings Date8/21/2020 (Estimated) OptionableNot Optionable NASDAQ:MBRX Rates by TradingView Receive MBRX News and Ratings via Email Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions How has Moleculin Biotech's stock been impacted by COVID-19 (Coronavirus)? Moleculin Biotech's stock was trading at $0.5051 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MBRX stock has increased by 113.8% and is now trading at $1.08. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Moleculin Biotech? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Moleculin Biotech. When is Moleculin Biotech's next earnings date? Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Moleculin Biotech. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech Inc (NASDAQ:MBRX) released its earnings results on Monday, May, 11th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). View Moleculin Biotech's earnings history. What price target have analysts set for MBRX? 3 brokerages have issued 12-month target prices for Moleculin Biotech's stock. Their forecasts range from $2.00 to $3.00. On average, they expect Moleculin Biotech's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 131.5% from the stock's current price. View analysts' price targets for Moleculin Biotech. Has Moleculin Biotech been receiving favorable news coverage? Headlines about MBRX stock have trended very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Moleculin Biotech earned a news impact score of -3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutMoleculin Biotech. Who are some of Moleculin Biotech's key competitors? Some companies that are related to Moleculin Biotech include CymaBay Therapeutics (CBAY), ProQR Therapeutics (PRQR), Fortress Biotech (FBIO), Affimed (AFMD), Chiasma (CHMA), Spero Therapeutics (SPRO), Hookipa Pharma (HOOK), REDHILL BIOPHAR/S (RDHL), Abeona Therapeutics (ABEO), Agile Therapeutics (AGRX), Obseva (OBSV), XOMA (XOMA), Ritter Pharmaceuticals (RTTR), Mallinckrodt (MNK) and Galera Therapeutics (GRTX). View all competitors. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), Gilead Sciences (GILD), vTv Therapeutics (VTVT), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Novavax (NVAX), Co-Diagnostics (CODX), Verastem (VSTM) and Exelixis (EXEL). Who are Moleculin Biotech's key executives? Moleculin Biotech's management team includes the following people: Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 59)Mr. Jonathan P. Foster, CFO & Exec. VP (Age 55)Dr. Donald H. Picker, Chief Scientific Officer (Age 73)Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory BoardDr. Robert C. Shepard, Chief Medical Officer (Age 67) What is Moleculin Biotech's stock symbol? Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX." Who are Moleculin Biotech's major shareholders? Moleculin Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Two Sigma Securities LLC (0.17%) and Raymond James Financial Services Advisors Inc. (0.14%). View institutional ownership trends for Moleculin Biotech. Which major investors are buying Moleculin Biotech stock? MBRX stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Securities LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for Moleculin Biotech. How do I buy shares of Moleculin Biotech? Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Moleculin Biotech's stock price today? One share of MBRX stock can currently be purchased for approximately $1.08. How big of a company is Moleculin Biotech? Moleculin Biotech has a market capitalization of $65.24 million. The company earns $-13,200,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Moleculin Biotech employs 9 workers across the globe. What is Moleculin Biotech's official website? The official website for Moleculin Biotech is www.moleculin.com. How can I contact Moleculin Biotech? Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160. This page was last updated on 6/5/2020 by MarketBeat.com Staff
